Enso Pilot Study for Chronic Low Back Pain

NCT ID: NCT03409783

Last Updated: 2018-11-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-14

Study Completion Date

2018-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enso is a portable device for the treatment of chronic and acute types of musculoskeletal pain. This study is being designed as a single blind, sham-controlled randomized clinical trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fifty subjects will be selected based on the inclusion criteria and then randomized to either the intervention group or the sham control group. Each subject will be randomly fitted with an Enso or a sham device and will be instructed to self-administer treatment daily for one hour or more per day for two weeks in both cohorts. Throughout the duration of the study, data will be recorded via a smartphone application regarding treatment usage and intensity, pain levels, the subject's impression of any changes in their functionality, and their opioid and non-opioid medication intake. Additional functional testing will be conducted at each study visit.

At the 2 week visit, the study blind will be broken, and subjects who were randomized to the sham group will be given the opportunity to cross over for an additional 2 week period using the active device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single blind, randomized, sham controlled study
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Devices are assigned per the randomization schedule, with the sham device identical to the active device in every way except that no neuromodulation is delivered. The neuromodulation that the active device delivers can be done in a way that causes no sensation, so subjects are not unmasked.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active or ENSO Group

Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.

Group Type ACTIVE_COMPARATOR

ENSO Device

Intervention Type DEVICE

An active ENSO device that delivers neuromodulation therapy.

Sham Group

Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.

Group Type SHAM_COMPARATOR

Sham Device

Intervention Type DEVICE

Sham Device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ENSO Device

An active ENSO device that delivers neuromodulation therapy.

Intervention Type DEVICE

Sham Device

Sham Device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Walk no further than 250 meters during a pre-study administration of the Six Minute Walk Test
2. Confirm that either they are able on their own to place the device (i.e., the gel pad) in its proper location, or they have a caretaker or family member who can assist them if needed
3. Mechanical (myofascial), axial back pain (focused around the spine)
4. 6/10 or greater level of pain
5. Functionally debilitated by their pain (e.g., difficulty walking)
6. Minimal radicular symptoms with no effect on functionality, medication, quality of life
7. Expressed desire to stop taking pain medications
8. Expressed desire to improve disability
9. 80% or greater of disability is due to pain in the low back (as opposed to other body areas)
10. Experiencing chronic pain for at least 6 months
11. Interested in being active, improving their functionality
12. Comfortable with using technology in daily life
13. Subject able to understand and grant informed consent
14. Documented adherence with clinic follow up visits per medical records
15. Has an email account
16. Above 18 years old

Exclusion Criteria

1. Patients that do not own or have access to a smartphone
2. Subject who, in the Investigator's opinion, does not demonstrate a strong desire to reduce opioid or other pain medication usage (e.g., opioid dependence)
3. Has spinal instability, joint instability, or grade 2 or greater spondylolisthesis with instability
4. Primary symptoms due to spinal stenosis
5. Source of back pain related to an acute nerve impingement
6. Diagnosis of cancer/malignant tumors in the last 5 years
7. Source of back pain is an infection
8. Prior spinal fusion surgery
9. Has a cardiac pacemaker, implanted defibrillator or other implanted electronic device
10. Has radicular pain symptoms that account for more than 20% of their pain and/or functional impairment
11. Has undergone surgery to solve pain related to the study indication in the past 6 months
12. Patients with history of opioid, alcohol or drug abuse in the last 5 years, per investigator discretion
13. Any psychiatric condition that may interfere with the study assessments or prevent the subject from complying with the requirements of the protocol, in the judgement of the investigator.
14. Inability to complete subjective data as required; e.g. on mobile application and questionnaires
15. Pregnant women (as determined by self-report)
16. Have severe epilepsy
17. Have severe form of cardiovascular disease
18. Any other disease, condition, or habit(s) that in the opinion of the Principal Investigator would interfere with study compliance or adversely affect study outcomes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, San Francisco

OTHER

Sponsor Role collaborator

Thimble Bioelectronics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bobby Tay, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Spine and Nerve Diagnostic Center

Roseville, California, United States

Site Status

University of California

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol 17-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.